testo-alternativo

Fiorina Paolo

Fiorina Paolo
Prof. Fiorina Paolo

Malattie Metaboliche e Diabetologia

Direttore dell'Unità Operativa di Endocrinologia e Diabetologia presso ASST Fatebenefratelli Sacco

Contacts

Hospital

ASST Fatebenefratelli Sacco

Phone: 02 63631

P.le Principessa Clotilde 3 20121 Milano

Curriculum

Prof. Paolo Fiorina is an internationally recognized leader in endocrinology, nephrology, and diabetes research. He graduated cum laude in Medicine from the University of Milan, specialized in Allergy and Clinical Immunology at the University of Parma, and earned a Ph.D. in Milan. He later completed a specialization in Internal Medicine at Vita-Salute San Raffaele University. His training was further enriched by a prestigious Research Fellowship at Harvard Medical School, where he launched a distinguished academic career and became Assistant Professor in 2009.


Today he holds key positions of global relevance:

  • Associate Professor of Endocrinology, Nephrology and Nutritional Sciences, University of Milan
  • Director of the International Reference Center for Type 1 Diabetes, Romeo and Enrica Invernizzi Pediatric Research Center – Sacco Hospital, Milan
  • Head of the Departmental Unit of Endocrinology and Diabetology at both Fatebenefratelli and Sacco Hospitals in Milan


Scientific Recognition and Academic Output

  • Author of more than 140 peer-reviewed articles in top-tier journals such as New England Journal of Medicine, Lancet, Science Translational Medicine, and Cell Stem Cell, with over 4,500 citations and an h-index of 44
  • Recipient of prestigious international honors, including Young Investigator Awards from the American Diabetes Association, the American Society of Nephrology, and the American Association of Immunology
  • Regular reviewer and grant committee member for major research agencies and foundations across Europe, North America, and Latin America
  • Editorial board member for several leading international scientific journals



Prof. Fiorina’s research has opened new therapeutic avenues for type 1 diabetes and diabetic kidney disease, focusing on innovative immune-based strategies. His career combines groundbreaking clinical expertise, high-impact scientific contributions, and a global network of collaborations, confirming him as one of the most authoritative voices worldwide in diabetes and endocrine disorders.